Chordia Therapeutics (TSE:190A) Interest Expense: 円-2.77 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
12 GF Score
Price 円78.00
! 2 Warning Signs
View Full Analysis

What is Chordia Therapeutics Interest Expense?

Chordia Therapeutics TSE:190A 12 Interest Expense is 円-2.77 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chordia Therapeutics's interest expense for the six months ended in Feb. 2026 was 円 -2.77 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2026 was 円-2.77 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chordia Therapeutics's Operating Income for the six months ended in Feb. 2026 was 円 -662.73 Mil. Chordia Therapeutics's Interest Expense for the six months ended in Feb. 2026 was 円 -2.77 Mil. Chordia Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chordia Therapeutics  (TSE:190A) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chordia Therapeutics's Interest Expense for the six months ended in Feb. 2026 was 円-2.77 Mil. Its Operating Income for the six months ended in Feb. 2026 was 円-662.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Feb. 2026 was 円0.00 Mil.

Chordia Therapeutics's Interest Coverage for the quarter that ended in Feb. 2026 is calculated as

Chordia Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Chordia Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Interest Expense Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Interest Expense
0.00 0.00 0.00 -8.75 0.00

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Interest Expense Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -2.77
TSE:190A
12GF Score
Chordia Therapeutics Inc TSE:190A
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-2.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of 円-2.77 Mil mean?
Chordia Therapeutics (TSE:190A) has a Interest Expense of 円-2.77 Mil as of Feb. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Chordia Therapeutics and its competitors.
Is Chordia Therapeutics' Interest Expense too high?
Chordia Therapeutics' current Interest Expense is 円-2.77 Mil. Overall, Chordia Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Interest Expense compare to VRTX and REGN?
Chordia Therapeutics' Interest Expense of 円-2.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current Interest Expense is 円-2.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Interest Expense of 円-2.77 Mil. The current Interest Expense is 円-2.77 Mil. Chordia Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Interest Expense is 円-2.77 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
12GF Score

Get the complete analysis for TSE:190A

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円78.00
Price